Major CNV publication cites OGT’s CNV service
OGT is proud to be associated with last week’s Nature publication entitled ‘Origins and functional impact of copy number variation in the human genome’ (doi:10.1038/nature08516). For the study, OGT, the pioneer of microarray technology, was chosen as the service provider, having delivered data of exceptional quality during evaluation.
“We are delighted to have been selected for the study due to the high quality of the data generated, and to have contributed to the Nature publication. Subsequently, we have generated in excess of 2 billion CNV data points using the Agilent platform and, most importantly, have achieved a consistently high quality data set,” commented Mike Evans, OGT’s CEO.
Today, Thursday October 22nd, at the 59th annual meeting of the American Society of Human Genetics in Honolulu, Hawaii, OGT is sponsoring the Invited Scientific Session ‘Impact of Structural Variation on Human Disease and Evolution’ which will be reporting on some of the lessons learnt from the most recent large-scale studies, such as HapMap3 and the 1,000 Genomes Project.
Efficient research with Genefficiency™ from OGT
Genefficiency, OGT’s high throughput genomic services, combines industry leading platforms, expert people and unparalleled sample processing power, to rapidly deliver high quality genomic data.
“By providing high sample throughput and exacting QC standards, we enable our customers to generate high quality genomic data more efficiently, particularly for CNV,” commented Gareth Thomson, OGT’s Director of Genomic Services.
OGT 656-09/2
“We are offering our customers the chance to sample Genefficiency for CNV analysis through our pilot study program, which not only allows researchers to make the most of data and resources in disease research, but can also secure a credit of pilot study costs,” he added.
Notes for editors:
About Oxford Gene Technology:
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. The OGT CytoSure™ cytogenetics array, labelling and interpretation software products provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomics in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
Find out more
For more information about any OGT product or service, please contact us.